Three Bays Capital’s Bristol-Myers Squibb BMY Stock Holding History

Three Bays Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-856,400	Closed	-$46.6M	–	20
2017 Q1	$46.6M	Buy	+856,400	New	+$47M	3.82%	13

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Three Bays Capital's BMY Position: Q2 2017 in Review

Three Bays Capital sold out of Bristol-Myers Squibb (BMY) in Q2 2017, closing a stake of 856,400 shares — an estimated $46.6M sold.

Three Bays Capital first reported a position in BMY in Q1 2017 and held it in 1 quarter. The position peaked at $46.6M in Q1 2017. 1,594 funds tracked by Wall St. Rank hold BMY as of Q2 2017.

Three Bays Capital reported no remaining Bristol-Myers Squibb position as of Q2 2017 after selling out during the quarter.
Three Bays Capital sold 856,400 Bristol-Myers Squibb shares in Q2 2017, an estimated $46.6M.
Three Bays Capital first reported a position in Bristol-Myers Squibb in Q1 2017 and held it in 1 quarter.
Three Bays Capital's Bristol-Myers Squibb position peaked at $46.6M in Q1 2017.
1,594 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2017.

Based on Three Bays Capital's 13F filing for Q2 2017, filed 14 Aug 2017.